Answers are grounded in this paper and cite their sources.
Jingbo Qiao1, Camryn D. Chung2, Elizabeth D. Cochran1 and Dai H. Chung1,2 1 Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA 2 Children’s Health, Dallas, TX 75235, USA Correspondence to: Dai H. Chung, email:dai.chung@utsouthwestern.edu Keywords: neuroblastoma; MYCN; PD-L1; CXCL10; immunotherapy Received: August 15, 2025 Accepted: October 19, 2026 Published: November 18, 2026 Copyright: © 2026 Qiao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Neuroblastoma (NB) is the most common extracranial solid tumor in children, and outcomes for patients with high-risk disease remain poor despite intensive multimodal therapy. MYCN amplification is associated with unfavorable prognosis and an immunologically “cold” tumor microenvironment (TME). This study investigated the impact of MYCN amplification on the expression of PD-L1 and the chemokine CXCL10, two important regulators of antitumor immunity. Analysis of NB patient datasets revealed that MYCN amplification was associated with reduced expression of both PD-L1 and CXCL10. Higher expression of PD-L1 and CXCL10 correlated with significantly improved overall survival. In contrast, PD-1 and PD-L2 showed weaker associations with MYCN status and were not linked to survival outcomes. In MYCN amplified NB cell lines, PD-L1 expression remained inducible by interferon-γ (IFNγ). Silencing MYCN further enhanced IFNγ-induced PD-L1 expression at both mRNA and protein levels, indicating that MYCN suppresses PD-L1 responsiveness. The BET inhibitor JQ1 reduced IFNγ-induced PD-L1 expression regardless of MYCN status, whereas inhibition of CXCL10 secretion was observed only in MYCN non-amplified cells. Retinoic acid (RA), a standard component of NB therapy, increased PD-L1 mRNA expression in all cell lines but increased PD-L1 protein expression primarily in MYCN non-amplified cells. Overall, these findings identify MYCN as a key regulator of immune signaling in NB and suggest that MYCN amplification contributes to an immune-cold tumor phenotype through suppression of PD-L1 and CXCL10 expression. MYCN status may therefore serve as a biomarker for immune stratification and guide the development of combination immunotherapeutic strategies for high-risk NB.
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: